NCT04540965View on ClinicalTrials.gov

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

December 8, 2020

Study Completion Date

December 8, 2020

Conditions
Drug Interaction
Interventions
DRUG

Telaglenastat

Glutaminase inhibitor

DRUG

Famotidine

Histamine-H2 Receptor Antagonist

DRUG

Placebo for famotidine

Placebo for Histamine-H2 Receptor Antagonist

Trial Locations (1)

Herston QLD 4006

Nucleus Network Brisbane Clinic (formerly Q-Pharm), Brisbane

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Calithera Biosciences, Inc

INDUSTRY